Cancer Care Centre Research Program is located at St George & Sutherland Clinical Campuses in Kogarah, NSW. Our program brings together interdisciplinary expertise in cell & molecular biology, extracellular vesicle, multi-omics, radiation oncology, urological oncology, novel imaging modalities and clinical trials, to improve outcomes for cancer patients.
Our goals
We advance patient-centred and clinically driven research to better understand how cancer starts, develops and spreads and to improve the diagnosis and treatment of prostate, breast and bladder cancers.
- Multi-omics biomarkers – discover transcriptomic, proteomic, lipidomic, metabolomic & microbiome signatures for personalised risk prediction, diagnosis and surveillance.
- Liquid biopsy – identify extracellular vesicle biomarkers for minimally invasive cancer detection and monitoring.
- Therapeutic resistance – unravel tumour-immune microenvironment drivers to guide new combination therapies.
- Innovative imaging – create next-generation modalities for early detection and risk stratification in urological cancers.
Research strengths
- Collaborative and multidisciplinary research team allowing for direct translation of knowledge.
- Direct access to specialist public and private clinics for patients with various cancer types.
- Cutting-edge next generation multi-omics approaches and liquid biopsy analysis platforms.
- Strong connections with community, industry partners and collaborators domestically and internationally.
- Extensive experience in clinical research including complex research ethics and randomised controlled trials.
Our results
- High-impact research output (>350 publications with >15,000 citations, team combined)
- Consistent grant funding success from NHMRC, CINSW, TROG, Ovarian Cancer Foundation, Pancreatic Cancer Foundation, PBCF, ANZUP, NSW Health and SSMRF.
- Successful supervision of >30 PhD, Masters and Honours students to completion.
- Paradigm-shifting research outcomes, including:
- the first RCT on the use of boost radiation in DCIS patients (Lancet);
- PSMA-PET/CT+MRI trial for clinically significant prostate cancer diagnosis (European Urology);
- the world-first landmark MRI trial for prostate cancer active surveillance (The Journal of Urology), and
- the establishment of a novel liquid biopsy platform using extracellular vesicle miRNAs for prostate cancer risk stratification.
